Neuralstem Licenses Cleveland Clinic Spinal Cord Injection ...( ROCKVILLE Md. Oct. 14 /- Neuralst...),Health

ROCKVILLE, Md., Oct. 14 /PRNewswire-FirstCall/ -- Neuralstem Inc., (Amex: CUR) today announced that it has licensed the rights to three inventions from Cleveland Clinic pertaining to Targeted Spinal Cord Therapeutics Delivery. All three inventions were developed by Dr. Nicholas Boulis MD, formerly of Cleveland Clinic, now at Emory University.

(Logo: http://www.newscom.com/cgi-bin/prnh/20061221/DCTH007LOGO )

"We are very pleased to have licensed-in these important delivery technology rights," said Neuralstem President & CEO, Richard Garr. "As we get ready to move into our expected human trial for ALS, we are focused on the optimal way to deliver our cell therapeutics to enhance the safety and efficacy of the treatments. Transplanting our cells directly into the spinal cord is a challenging but necessary part of trying to treat diseases of the spinal cord, not only in ALS, but in other spinal cord injuries and diseases." Garr went on to say, "The technology licensed today will help us to meet those goals."

Neuralstem will use this technology in its clinical trial for ALS (Amytrophic Lateral Sclerosis, or Lou Gehrig's disease). The company anticipates filing its IND (Investigational New Drug) application with the FDA for the ALS trial in the next few weeks, and hopes to start the trial early in 2009.

"Neuralstem is a second generation stem cell company," said Garr, "built not so much to do basic research and discovery, as to optimize our discovery of neural stem cells, and take them into the clinic and into patients. We believe that our technology answers many of the issues that have held the field back, and makes it possible to bu
'/>"/>